Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 2, 2011, Pages 100-108

  Brumme, Zabrina L ^a,b,c   Li, Chun ^c,d   Miura, Toshiyuki ^c,e   Sela, Jennifer ^c   Rosato, Pamela C ^c   Brumme, Chanson J ^b,c   Markle, Tristan J ^a   Martin, Eric ^a,f   Block, Brian L ^c   Trocha, Alicja ^c   Kadie, Carl M ^a   Allen, Todd M ^c   Pereyra, Florencia ^c   Heckerman, David ^a   Walker, Bruce D ^g   Brockman, Mark A ^a,b,c,g  

^a SIMON FRASER UNIVERSITY   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f MICROSOFT RESEARCH   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocyte; elite controller; HIV 1; HLA class I; immune escape; Pol; viral replication capacity

Indexed keywords

GAG PROTEIN; GREEN FLUORESCENT PROTEIN; HLA ANTIGEN CLASS 1; HLA B51 ANTIGEN; HLA B57 ANTIGEN; INTEGRASE; POL PROTEIN; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HLA SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIREMIA; VIRUS ATTENUATION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

HIV INFECTIONS; HIV INTEGRASE; HIV LONG-TERM SURVIVORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; RECOMBINATION, GENETIC; VIRULENCE; VIRUS REPLICATION;

EID: 78751640260     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181fe9450     Document Type: Article

References (50)

1. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406-416.
2. Quinones-Mateu ME, Ball SC, Marozsan AJ, et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol. 2000;74:9222-9233.
3. Blaak H, Brouwer M, Ran LJ, et al. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation tovirus load in long-term survivors of HIV-1 infection. J Infect Dis. 1998;177: 600-610.
4. Miura T, Brockman MA, Brumme CJ, et al. Genetic characterization of Human Immunodeficiency Virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol. 2008;82: 8422-8430.
5. Navis M, Schellens I, van Baarle D, et al. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol. 2007;179:3133-3143.
6. Lassen KG, Lobritz MA, Bailey JR, et al. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog. 2009;5:e1000377.
7. Chopera DR, Woodman Z, Mlisana K, et al. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog. 2008;4:e1000033.
8. Goepfert PA, Lumm W, Farmer P, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med. 2008;205:1009-1017.
9. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73:10489-10502.
10. Troyer RM, Collins KR, Abraha A, et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol. 2005;79:9006-9018.
11. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol. 2007;5:141-151.
12. Brockman MA, Schneidewind A, Lahaie M, et al. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol. 2007;81:12608-12618.
13. Schneidewind A, Brockman MA, Yang R, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol. 2007;81:12382-12393.
14. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol. 2006;80:3617-3623.
15. Crawford H, Prado JG, Leslie A, et al. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J Virol. 2007;81:8346-8351.
16. Crawford H, Lumm W, Leslie A, et al. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med. 2009;206:909-921.
17. Boutwell CL, Rowley CF, Essex M. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol. 2009;83:2460-2468.
18. Ueno T, Motozono C, Dohki S, et al. CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol. 15 2008;180:1107-1116.
19. Bailey JR, O'Connell K, Yang HC, et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol. 2008;82:7395-7410.
20. Miura T, Brockman MA, Brumme ZL, et al. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol. 2009;83:140-149.
21. Miura T, Brumme ZL, Brockman MA, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol. 2010;84:7581-7591.
22. Miura T, Brockman MA, Schneidewind A, et al. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphotye recognition. J Virol. 2009;83: 2743-2755.
23. Troyer RM, McNevin J, Liu Y, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009;5:e1000365.
24. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol. 1998;72:3773-3778.
25. Weber J, Chakraborty B, Weberova J, et al. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol. 2005;43:1395-1400.
26. Paredes R, Sagar M, Marconi VC, et al. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol. 2009;83:2038-2043.
27. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther. 2004;2:147-151.
28. Gandhi RT, Wurcel A, Rosenberg ES, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis. 2003;37: 1693-1698.
29. Brockman MA, Tanzi GO, Walker BD, et al. Use of a novel GFP reporter cell line to examine replication capacity of CXCR4-and CCR5-tropic HIV-1 by flow cytometry. J Virol Methods. 2006;131:134-142.
30. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and Immunologic Heterogeneity among Persons Who Control HIV Infection in the Absence of Therapy. J Infect Dis. 2008;197:563-571.
31. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003;52: 696-704.
32. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100:9440-9445.
33. Galli RA, Sattha B, Wynhoven B, et al. Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance. J Clin Microbiol. 2003; 41:2900-2907.
34. Brumme ZL, John M, Carlson JM, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef Proteins. PloS ONE. 19 2009;4:e6687.
35. Honeyborne I, Prendergast A, Pereyra F, et al. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol. 2007;81: 3667-3672.
36. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535-551.
37. Kawashima Y, Pfafferott K, Frater J, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 2009;458:641-645.
38. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 1997;3:212-217.
39. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol. 2004;4:630-640.
40. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004; 432:769-775.
41. Altfeld M, Kalife ET, Qi Y, et al. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med. 2006;3:e403.
42. Tomiyama H, Sakaguchi T, Miwa K, et al. Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Hum Immunol. 1999;60:177-186.
43. Kawashima Y, Kuse N, Gatanaga H, et al. Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101. J Virol. 2010;84:7151-7160.
44. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA. 2000;97: 2709-2714.
45. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405-411.
46. Klein MR, van der Burg SH, Hovenkamp E, et al. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag-and RT-specific cytotoxic T lymphocyte responses. J Gen Virol. 1998;79 (Pt 9): 2191-2201.
47. Allen TM, Altfeld M, Geer SC, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol. 2005;79:13239-13249.
48. Brumme ZL, Brumme CJ, Carlson J, et al. Marked epitope and allele-specific differences in rates of mutation in HIV-1 Gag, Pol and Nef CTL epitopes in acute/early HIV-1 infection. J Virol. 2008;82:9216-9227.
49. Li B, Gladden AD, Altfeld M, et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol. 2007;81:193-201.
50. Lobritz MA, Marozsan AJ, Troyer RM, et al. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol. 2007;81:8258-8269.